UNSPSC 51183604: Exenatide synthetic

This classification denotes an anti-diabetic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9P1872D4OL. European Medicines Agency schedules Exenatide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21818. Exenatide synthetic generally arises in the molecular formula C184H282N50O60S. The term 'exenatide synthetic' is a U.S. FDA Orange Book designation. Most nations, for tariff and trade purposes, schedule exenatide synthetic under HS 29332990. SMILES:.

UNSPSC 51183604 Exenatide synthetic is a Commodity code for a specific pharmaceutical product — a glucagon-like peptide-1 (GLP-1) receptor agonist injectable used to treat type 2 diabetes. State and local government procurement under this code reflects purchases of the drug itself for use in public health programs, correctional facilities, and public employee health plans. The issuing bodies span state health departments, county correction systems, state Medicaid agencies, and municipal health clinics. Exenatide synthetic solicitations typically appear as direct pharmaceutical acquisitions, often bundled with other diabetic medications or as standalone drug formulary additions managed through state purchasing cooperatives or group purchasing organizations.

The source provided contains no recent state and local contract opportunities under this code, and therefore does not support characterization of geographic concentration, issuing-body frequency, or representative recent solicitations. Without posted RFP, RFQ, IFB, or ITB notices in the opportunities block, the current activity level under UNSPSC 51183604 cannot be assessed.